Hall W T, Madden D L, Mundon F K, Brandt D E, Clarke N A
Am J Epidemiol. 1977 Jul;106(1):72-5. doi: 10.1093/oxfordjournals.aje.a112435.
Serologic evidence now confirms epidemiologic evidence that human immune serum globulin (ISG) protects susceptible patients from hepatitis A provided it is administered prior to exposure to the virus. In two wards of young patients housed at the Lynchburg (Virginia) Training School and Hospital for the mentally retarded, 44 out of 60 patients had no detectable antibody to hepatitis A prior to an epidemic which took place there in 1970; 12 of 19 non-immunized susceptible patients contracted the disease, while only four of 25 patients receiving ISG developed hepatitis. These four were probably infected with the virus prior to ISG administration. Of the 16 patients with pre-existing antibody, none showed any signs of symptoms of hepatitis.
血清学证据现已证实流行病学证据,即人免疫血清球蛋白(ISG)能保护易感患者免受甲型肝炎感染,前提是在接触病毒之前给予该药物。在弗吉尼亚州林奇堡智障人士培训学校和医院收治年轻患者的两个病房中,1970年那里发生疫情之前,60名患者中有44人检测不到甲型肝炎抗体;19名未免疫的易感患者中有12人感染了该疾病,而接受ISG治疗的25名患者中只有4人患上了肝炎。这4人可能在给予ISG之前就已感染病毒。在16名已有抗体的患者中,无人出现肝炎的任何症状体征。